Artiva Biotherapeutics Inc [ARTV] stock prices are up 35.66% to $3.31 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ARTV shares have gain 10.33% over the last week, with a monthly amount drifted -38.25%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Artiva Biotherapeutics Inc [NASDAQ: ARTV] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $20. Previously, Wedbush started tracking the stock with Outperform rating on August 13, 2024, and set its price target to $18. On August 13, 2024, TD Cowen initiated with a Buy rating. Needham started tracking the stock assigning a Buy rating and suggested a price target of $23 on August 13, 2024. Jefferies initiated its recommendation with a Buy and recommended $21 as its price target on August 13, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on August 13, 2024, and assigned it a price target of $23.
The stock price of Artiva Biotherapeutics Inc [ARTV] has been fluctuating between $2.29 and $17.31 over the past year. Currently, Wall Street analysts expect the stock to reach $20.5 within the next 12 months. Artiva Biotherapeutics Inc [NASDAQ: ARTV] shares were valued at $3.31 at the most recent close of the market. An investor can expect a potential return of 519.34% based on the average ARTV price forecast.
Analyzing the ARTV fundamentals
The Artiva Biotherapeutics Inc [NASDAQ:ARTV] reported sales of 0.25M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -268.06%, Pretax Profit Margin comes in at -219.87%, and Net Profit Margin reading is -219.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -10.1 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.02 points at the first support level, and at 0.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.78, and for the 2nd resistance point, it is at 6.24.
Ratios To Look Out For
It’s worth pointing out that Artiva Biotherapeutics Inc [NASDAQ:ARTV]’s Current Ratio is 15.39. In addition, the Quick Ratio stands at 15.39 and the Cash Ratio stands at 3.28. Considering the valuation of this stock, the price to sales ratio is 322.59, the price to book ratio is 0.43.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Jul 22 ’24 when 8.33 million shares were purchased. 10% Owner, 5AM Partners VI, LLC completed a deal on Jul 22 ’24 to buy 0.83 million shares. Meanwhile, 10% Owner venBio Global Strategic Fund I bought 0.42 million shares on Jul 22 ’24.
